Enalapril: Clinical Evidence & Trials
Enalapril is an ACE inhibitor that lowers blood pressure, reduces cardiac workload, and provides kidney protection in hypertension, heart failure, and diabetic nephropathy.
ACE inhibitors have landmark trial evidence for heart failure, post-MI survival, CKD progression, and cardiovascular risk reduction.
Evidence Strength
Level A (Strong) — among the most extensively studied cardiovascular drugs with benefits shown across mortality, hospitalisation, and renal endpoints.
Key Clinical Trial Findings
- •CONSENSUS (1987) — enalapril reduced mortality by 40% at 6 months in severe heart failure (NYHA IV)
- •SOLVD (1991–1992) — enalapril improved survival and reduced hospitalisations in HFrEF
- •HOPE (2000) — ramipril reduced CV death, MI, and stroke by 22% in high-risk patients without HF (N=9,297)
- •PROGRESS (2001) — perindopril-based regimen reduced recurrent stroke by 43% in stroke/TIA patients
- •Lewis et al. NEJM 1993 — captopril reduced doubling of creatinine and ESRD in type 1 diabetic nephropathy
Numbers Needed to Treat (NNT)
Heart failure mortality: NNT ≈ 9 over 6 months (CONSENSUS). Post-MI: NNT ≈ 30 to save 1 life over 5 years. Diabetic nephropathy: NNT ≈ 8 to prevent ESRD over 3 years.
Guideline Recommendations
Class I recommendation (NICE, ESC, ACC/AHA) for HFrEF, post-MI LV dysfunction, diabetic nephropathy, and CKD with proteinuria. ESC HF Guidelines 2021 mandate ACE inhibitor (or ARNi) for all HFrEF patients without contraindication.
Conditions Treated with Enalapril
Questions about your medication?
Our AI Symptom Checker analyses your symptoms and suggests the most likely diagnoses — including relevant medications.
Use AI Symptom Checker →